Tirzepatide dosing chart (mg to units)
A tirzepatide amount and a syringe marking are connected by concentration. This chart uses the app's documented 10 mg vial and six preset amounts. PinPoint describes the generic compound as acting at GIP and GLP-1 receptors and places it in the GLP-1 category. The cited prescribing information is for Mounjaro.
Vial concentration
Water mL is treated as final solution mL in these columns.
| Vial contents | 1 mL water | 2 mL water | 3 mL water |
|---|---|---|---|
| 10 mg | 10 mg/mL10 U-100 units per mg | 5 mg/mL20 U-100 units per mg | 3.3333 mg/mL30 U-100 units per mg |
Vial source: PinPoint/Data/CompoundLibrary.swift, line 224, the Tirzepatide entry. One documented amount is available.
Preset doses in PinPoint
Preset amounts are a conversion reference, not a personal dosing plan.
| Preset amount | 10 mg + 1 mL | 10 mg + 2 mL | 10 mg + 3 mL |
|---|---|---|---|
| 2.5 mg | 25 units | 50 units | 75 units |
| 5 mg | 50 units | 100 units | 150 unitsover one syringe |
| 7.5 mg | 75 units | 150 unitsover one syringe | 225 unitsover one syringe |
| 10 mg | 100 units | 200 unitsover one syringe | 300 unitsover one syringe |
| 12.5 mg | 125 unitsover one syringeexceeds vial contents | 250 unitsover one syringeexceeds vial contents | 375 unitsover one syringeexceeds vial contents |
| 15 mg | 150 unitsover one syringeexceeds vial contents | 300 unitsover one syringeexceeds vial contents | 450 unitsover one syringeexceeds vial contents |
Cited amounts
| Amount (mg) and source context | Frequency as stated | Route as stated | 10 mg + 1 mL | 10 mg + 2 mL | 10 mg + 3 mL | Source |
|---|---|---|---|---|---|---|
| 2.5 mgAdult label escalation step; increases are separated by at least 4 weeks. | Once weekly | Subcutaneous | 25 units | 50 units | 75 units | Tirzepatide prescribing information (Mounjaro)Regulatory labelRetrieved 2026-10-05 |
| 5 mgAdult label escalation step; increases are separated by at least 4 weeks. | Once weekly | Subcutaneous | 50 units | 100 units | 150 unitsover one syringe | Tirzepatide prescribing information (Mounjaro)Regulatory labelRetrieved 2026-10-05 |
| 7.5 mgAdult label escalation step; increases are separated by at least 4 weeks. | Once weekly | Subcutaneous | 75 units | 150 unitsover one syringe | 225 unitsover one syringe | Tirzepatide prescribing information (Mounjaro)Regulatory labelRetrieved 2026-10-05 |
| 10 mgAdult label escalation step; increases are separated by at least 4 weeks. | Once weekly | Subcutaneous | 100 units | 200 unitsover one syringe | 300 unitsover one syringe | Tirzepatide prescribing information (Mounjaro)Regulatory labelRetrieved 2026-10-05 |
| 12.5 mgAdult label escalation step; increases are separated by at least 4 weeks. | Once weekly | Subcutaneous | 125 unitsover one syringeexceeds vial contents | 250 unitsover one syringeexceeds vial contents | 375 unitsover one syringeexceeds vial contents | Tirzepatide prescribing information (Mounjaro)Regulatory labelRetrieved 2026-10-05 |
| 15 mgAdult label escalation step; increases are separated by at least 4 weeks. | Once weekly | Subcutaneous | 150 unitsover one syringeexceeds vial contents | 300 unitsover one syringeexceeds vial contents | 450 unitsover one syringeexceeds vial contents | Tirzepatide prescribing information (Mounjaro)Regulatory labelRetrieved 2026-10-05 |
How to read this chart
Find the concentration column. Divide the amount by that concentration. Multiply the mL value by 100 for U-100 units. Match the amount units before dividing.
units = dose ÷ (vial mg ÷ water mL) × 100
Amount and volume
One mg equals 1,000 mcg; 100 U-100 units equals 1 mL. Concentration connects amount to volume. Read the full conversion guide.
Five days in the level model
Tirzepatide has a stored elimination half-life of 120 hours, or five days. Its library schedule text is Every 7 days, so the reference interval between entries is longer than one modeled half-life. This distinction helps explain why the timeline covers the days between logged events rather than treating each event as an isolated point. The actual dates and times in a log position those events; the 120-hour value supplies the decay timescale used around them. Neither field changes the concentration of a vial.
What the app stores about absorption
The tirzepatide record pairs an 80% base bioavailability value with a 20-hour peak-time parameter. Its source annotation uses prescribing-label pharmacology and mentions a broader observed timing range, while the software keeps a single number for calculations. PinPoint marks the molecule's research status as FDA-approved. The chart's catalog vial is a separate reference from that status tag. Reading the timing inputs as model settings keeps the hour-based level display distinct from the immediately calculated mL and syringe-unit values in these tables.
The six rows and their limits
The exact preset list is 2.5, 5, 7.5, 10, 12.5, and 15 mg. Subcutaneous is the route recorded alongside those amounts, and compounded vial is the delivery form. With a 10 mg vial, the final two presets are larger than the vial's entire contents. Their rows therefore carry a contents flag as well as any volume flag. Keeping those rows visible preserves the app's full preset list while making the mismatch with this particular vial size easy to see.
Following one row across the water columns
A supplier-catalog entry is the source of the 10 mg tirzepatide vial amount. For the 2.5 mg row, that is one quarter of the vial. One quarter of a 1 mL solution is 0.25 mL; one quarter of a 2 mL solution is 0.5 mL; one quarter of a 3 mL solution is 0.75 mL. The corresponding U-100 markings are 25, 50, and 75. This fraction-based reading explains why the columns differ even though the amount at the left of the row stays fixed.
Questions about the conversion
What concentration is Tirzepatide at 10 mg in 1 mL?
10 mg divided by 1 mL is 10 mg per mL. That volume spans 100 U-100 syringe units.
How does 2 mL change the concentration of this Tirzepatide vial?
10 mg divided by 2 mL is 5 mg per mL, half the concentration in the 1 mL column.
What does the 3 mL column mean for Tirzepatide?
10 mg divided by 3 mL is approximately 3.3333 mg per mL. The full 3 mL volume corresponds to 300 U-100 units.
How many units is 2.5 mg of Tirzepatide from this vial in 2 mL?
2.5 mg divided by 5 mg per mL is 0.5 mL, or 50 U-100 units.
How many units is the 2.5 mg cited amount of Tirzepatide from a 10 mg vial in 2 mL?
The arithmetic is 2.5 mg ÷ 5 mg/mL × 100 = 50 U-100 units (0.5 mL). The amount is cited in Tirzepatide prescribing information (Mounjaro). Adult label escalation step; increases are separated by at least 4 weeks.
Track your calculations in the app
PinPoint for iOS brings vial setup, unit conversion, dose logs, site rotation, and protocol tracking together. Enter vial size and water volume for concentration and syringe units, then log injections with compound, dose, site, and pain level.
Get PinPoint on the App Store